Skip to main content
Premium Trial:

Request an Annual Quote

Danaher to Acquire Abcam for $5.7B

NEW YORK – Danaher said on Monday that it has entered into a definitive agreement to acquire protein consumables supplier Abcam for approximately $5.7 billion. 

Danaher will acquire all outstanding shares of Abcam for $24 per share in cash. Abcam is expected to operate as a standalone company and brand within Danaher's Life Sciences segment, Danaher said in a statement. The deal is expected to close in mid-2024 and is subject to customary conditions. Danaher said it expects to fund the acquisition with cash on hand and proceeds from the issuance of commercial paper.

Cambridge, UK-based Abcam offers antibodies, reagents, biomarkers, and assays for drug discovery, life sciences research, and diagnostics. According to the firm, which was founded in 1998, its tools and technologies are used by about 750,000 researchers. 

The acquisition will further Danaher's "strategy to help map complex diseases and accelerate the drug discovery process," the Washington, D.C.-based conglomerate said.

"Abcam's long track record of innovation, outstanding product quality, and breadth of antibody portfolio positions them as a key partner for the scientific community," Danaher President and CEO Rainer Blair said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.